CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31 ...

The release of Phase III Stage 1 data for gotistobart (BNT316/ONC-392) at NACLC 2025 marks one of the most significant ...

XmAb819 demonstrated a manageable safety profile with primarily grade 1 or 2 cytokine release syndrome and no neurotoxicity in ccRCC patients. The trial involved 69 patients, with a 25% objective ...

March Bio is continuing enrollment in the Phase 2 trial, with the Independent Data Monitoring Committee’s approval to advance to Simon Stage 2 of the Phase 2 trial. The Company anticipates presenting ...

A phase 1/2 clinical trial examining the CRISPR-engineered allogeneic chimeric antigen receptor (CAR)-T candidate AVC-203 (QUADvance) has been approved by the FDA and the European Medicines Agency ...

Elon Musk is pushing SpaceX toward an $800 billion valuation for a public listing next year, and the entire move leans ...

We are delighted that isupartob sodium has been recognized as a first-in-class therapy through the award of its International Nonproprietary Name (INN), which includes a new and distinctive suffix.

By Patricia Marins in Rio de Janeiro The People's Liberation Army Navy (PLAN) of China continues to expand at a staggering ...

CTD402’s ready-to-use manufacturing platform eliminates the 1-2 month delays inherent to autologous CAR-T therapies-delays that can be life-threatening for patients with rapidly progressive disease.

And GSK announced Thursday that the FDA had approved its medication gepotidacin, with the brand name Blujepa, as oral tablets ...

Under pressure from consent decrees, lawsuits and grand jury recommendations, Southern California counties take measures to ...

Keller Rinaudo Cliffton, Harvard '09, is the CEO of Zipline, a global logistics company pioneering autonomous drone delivery ...